Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting....here's the correct link I believe:
https://wwwnc.cdc.gov/eid/article/27/10/21-1427_article
Regarding immune status, 25/44 (56.8%) were fully vaccinated with BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.comExternal Link); 3/6 workers who had a history of COVID-19 were vaccinated with a single injection, according to the guidelines of France (2) (Table). Several BNT162b2 batch numbers were involved. Vaccine temperature had been monitored and electronically recorded by LogTag Analyzer (LogTag Recorders, http://www.logtag-recorders.comExternal Link) without any break in the cold chain. The attack rate was 15/25 (60.0%) in fully vaccinated miners, 6/15 (40.0%) in those partially vaccinated or with a history of COVID-19, and 3/4 (75%) in those not vaccinated. Attack rate was 0/6 among persons with a previous history of COVID-19 versus 63.2% among those with no previous history (Table). No other factors were found to be associated with the risk for infection.
I've heard https://www.ally.com/invest/ will but don't know for sure. At .01 per share I'm not really interested in finding out.
Ally Invest requires a minimum opening purchase of $100 per order in OTCBB and Pink Sheet stocks, and adds 1¢ per share on the entire order for stocks priced less than $2. Ally Invest doesn’t accept opening trades for stocks below 1¢ per share.
Well we all hope you’re right and I’m wrong. :)
I think most on this board are holding shares so I hope someday they get their $hit together and file.
Unless someone has insider info I see no reason to buy any of these. Why would you want $$ tied up in something that you can't trade. Maybe throw a few $$ at it as a lotto but that's about it. Those calling for $5-$10 on this one are smoking some good stuff imo! Heck if it ever goes over $1 again, I'll smoke with em lol.
kt
Got me excited for a minute...thought I had missed a filing. Ugg...less than $1200 traded. Probably penny traders opening Ally accounts to get some of these CE's.
kt
I was wondering if that had something to do with it...thanks for the reply!
kt
I guess my question is why did NIH say:
There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of GM-CSF inhibitors for the treatment of hospitalized patients with COVID-19.
And then in the very next paragraph say:
Preliminary data from a double-blind, placebo-controlled randomized trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor. However, preliminary data from a large, double-blind randomized trial of otilimab (primary endpoint: alive and free of respiratory failure at Day 28) and published results of a small, double-blind randomized trial of mavrilimumab (primary endpoint: proportion alive and off supplemental oxygen at Day 14) did not show a survival benefit for the GM-CSF inhibitors compared to placebo.11-13 The study populations differed; the lenzilumab and mavrilimumab studies primarily included patients on room air or low-flow oxygen and excluded patients receiving mechanical ventilation, whereas the otilimab study included only patients receiving high-flow oxygen, noninvasive ventilation, or invasive mechanical ventilation. Each of these GM-CSF inhibitors remains under investigation.
Why not just recommend lenzilumab since it clearly shows a significant improvement and the other 2 do not?
Do you think these Covid-19 guidelines put out by NIH will have a bearing on our EUA? Seems strange that they didn't recommend lenzilumab. Maybe because it doesn't have EUA yet?
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/gm-csf-inhibitors/
Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
Drug Info
Clinical Data
Last Updated: July 8, 2021
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a myelopoietic growth factor and proinflammatory cytokine that plays a central role in a broad range of immune-mediated diseases. GM-CSF, secreted by macrophages, T-cells, mast cells, natural killer cells, endothelial cells, and fibroblasts, regulates macrophage number and function. It acts as a pro-inflammatory signal, prompting macrophages to launch an immune cascade that ultimately results in tissue damage.1,2 GM-CSF is believed to be a key driver of lung inflammation in severe and critical COVID-19 pneumonia, operating upstream of other pro-inflammatory cytokines and chemokines.1-6 Anti-GM-CSF monoclonal antibodies may mitigate inflammation by inhibiting this signaling axis upstream and thus minimizing downstream production of numerous pro-inflammatory mediators involved in the pathogenesis of COVID-19.7 Gimsilumab, lenzilumab, namilumab, and otilimab target GM-CSF directly, neutralizing the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.1,8,9 Mavrilimumab targets the alpha subunit of the GM-CSF receptor, blocking intracellular signaling of GM-CSF.8,10 None of these agents are currently FDA-approved for any indication.
Recommendation
There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of GM-CSF inhibitors for the treatment of hospitalized patients with COVID-19.
Rationale
Clinical data are lacking to definitively establish the potential benefits and risks associated with the use of GM-CSF inhibitors in patients with COVID-19. Preliminary data from a double-blind, placebo-controlled randomized trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor. However, preliminary data from a large, double-blind randomized trial of otilimab (primary endpoint: alive and free of respiratory failure at Day 28) and published results of a small, double-blind randomized trial of mavrilimumab (primary endpoint: proportion alive and off supplemental oxygen at Day 14) did not show a survival benefit for the GM-CSF inhibitors compared to placebo.11-13 The study populations differed; the lenzilumab and mavrilimumab studies primarily included patients on room air or low-flow oxygen and excluded patients receiving mechanical ventilation, whereas the otilimab study included only patients receiving high-flow oxygen, noninvasive ventilation, or invasive mechanical ventilation. Each of these GM-CSF inhibitors remains under investigation.
Clinical Data for COVID-19
Lenzilumab, mavrilimumab, and otilimab have been evaluated in clinical trials in hospitalized adults with SARS-CoV-2 pneumonia.11-13 Clinical data are not yet available for gimsilumab or namilumab. The Panel’s recommendations are based on the results of the available clinical studies. Clinical data on the use of anti-GM-CSF monoclonal antibodies for the treatment of COVID-19 are summarized in Table 4b.
Nice!
Telcon RF added that it plans to seek approval to import the monoclonal antibody drug if the US Food and Drug Administration grants emergency use authorization for lenzilumab.
If Humanigen obtains emergency use authorization based on the company’s phase 3 clinical trial of lenzilumab, Telcon RF and KPM Tech could skip additional clinical studies in South Korea, which will speed up introduction of the COVID-19 treatment in the country, an official from Telcon RF said.
Hard to know what to believe anymore. This out of Israel today:
https://www.deseret.com/coronavirus/2021/7/20/22584134/whats-going-on-in-israels-outbreak-among-vaccinated-people
The people who are not testing positive in the current outbreak are those who have had COVID-19 previously and recovered. These people account for 9% of Israel’s population but less than 1% of recent infections, according to Kovler’s analysis. This has brought new questions about whether natural infections are more protective against the delta variant than vaccinations — but the answer is not yet certain.
kt
If that's the case, they would be better off to wait until next year to do anything.....catch all the tax loss selling at years end.
kt
Especially with the news coming out of the UK today:
https://www.reuters.com/business/healthcare-pharmaceuticals/60-people-being-admitted-uk-hospitals-had-two-covid-jabs-adviser-2021-07-19/
I don't know if vaccines are the answer.
https://www.reuters.com/business/healthcare-pharmaceuticals/60-people-being-admitted-uk-hospitals-had-two-covid-jabs-adviser-2021-07-19/
We need a good therapeutic. Do you know of any? :)
kt
It's possible but even if I was 100% on board I'm 100% against the government putting restrictions on unvaccinated people.
kt
Better get some land and start being self sufficient. Not so much land of the free anymore. :(
https://www.breitbart.com/clips/2021/07/13/sebelius-unvaccinated-americans-should-not-be-allowed-to-work-have-access-to-children/?fbclid=IwAR2dUrkAkzspTb33m0fOuMVMzsP7eUhn1md07LGEoi_GZYaCBMZTLfxS05Q#
$ATOM Added some $17.50's...small caps getting hit hard today.
There are four major risks associated with high numbers of infections. These are an increase in hospitalisations and deaths, more ‘Long-COVID’; workforce absences (including in the NHS); and the increased risk of new variants emerging. The combination of high prevalence and high levels of vaccination creates the conditions in which an immune escape variant is most likely to emerge. The likelihood of this happening is unknown, but such a variant would present a significant risk both in the UK and internationally.
Good read...thanks.
kt
But that's the Magic way.....just go short on everything that we buy and you'll retire early lol!
I think we're a product of our environment to some degree. My wife is probably going to be forced out of her job for not taking the vaccine before she's eligible to retire next March so the vaccine push makes me a little bitter. She also has a friend who has a 19 year old son in the hospital with Myocarditis after getting the vaccine and is not doing well. On the other side, we had a friend that died of Covid, my son-in-law is vaccinated and my daughter isn't(probably some interesting conversations in that household). I understand both sides to this issue but don't like the hatred portrayed if you're not in agreement. This should be an individual choice. The world has sure changed in the last couple of years. Makes me wonder what the world will be like for my grandchildren. :(
The last part of my reply wasn't directed at you EDF, just generally the world we live in now. We might have a difference of opinion but I still value and respect yours!
kt
What is an Emergency Use Authorization (EUA)? An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic.
Of course with any public reporting system like this you're going to have issues. I follow both my doctors advice and my sister's(she reviews IND applications for the FDA) who both have reservations about the vaccine. I also don't like to see this vaccine pushed on children as my doctor has seen a few cases of Myocarditis in teenagers and I live in a small rural area. I'm pretty sure most of them are not even reported on VAERS.
Audre Lorde said, "It is not our differences that divide us. It is our inability to recognize, accept, and celebrate those differences." Sadly these differences are not tolerated let alone celebrated too much anymore. Just my 2 cents. :)
kt
From Ameritrade if anyone is interested:
On September 28, 2021, new amendments to Rule 15c-211 under the Securities Exchange Act of 1934 go into effect to enhance investor protection and improve issuer transparency. These amendments restrict the ability of market makers to publish quotations for those companies that have not made required current financial and company information available to regulators and investors. Ahead of the regulatory enforcement date, TD Ameritrade will only accept orders to liquidate positions -(i.e. no new buy orders) starting in mid-August 2021. Please note: After the amendment officially goes into effect on September 28, 2021, it may be more difficult to liquidate these securities. Quoting and
market liquidity may also be very limited.
https://www.tdameritrade.com/retail-en_us/resources/pdf/TDA101550.pdf
kt
Been wanting to play some out of the money puts but the premiums are too pricy imo. Haven't played much of anything lately except $ATOM which I have been adding on dips under $20...waiting on Mikey's train to take off($HGEN) lol.
lol...that "problem" made you a ton of $$ a few months ago. :)
I would like to see a little more volume but it's nice to see green. Hopefully those calls pay off!!
kt
I'll take it! No viagra for me tonight!! Whoo hoo!
Have quite a bit invested here so I'm right there with you! See no reason why it wouldn't but nothing surprises me anymore. It's either a crazy world or I'm just getting old and cynical lol!
kt
Very true. I wouldn't even be surprised if $HGEN didn't get EUA. They can always say they have manufacturing or some other issues to work out.....nothing would surprise me anymore! Pretty sad!
kt
Wow...there goes the penny market.
And now look at what is happening in the EU. Soon you won't be able to work or eat unless you have the vaccine.
The key measure announced by Macron will make the EU Digital Covid Certificate — commonly called “health pass” — mandatory in all cultural venues, including cinemas, theaters and concert halls starting on July 21. Starting in August, the health pass will be mandatory in cafes, shops, restaurants, as well as trains and planes, among other places.
https://variety.com/2021/global/news/emmanuel-macron-covid-health-pass-mandatory-1235017731/
$ATOM...like this here under $20.
https://www.fool.com/investing/2021/07/06/why-atomera-stock-surged-22-higher-in-june/
And now they want to go door to door to push the vaccine. Unbelievable!
https://www.foxnews.com/politics/white-house-defends-door-to-door-vaccination-push-amid-backlash
kt
It's coming....perfect storm brewing here!
kt